申请人:OXiGENE, Inc.
公开号:US08877967B2
公开(公告)日:2014-11-04
This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
本发明涉及化合物I的复合物及其在治疗需要调节
蛋白酶卡
特普西K或卡
特普西L的情况下的治疗方法。